EICHORCondition: Psoriasis · Sponsor: Amgen
This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of apremilast (CC-10004) in subjects with mild to moderate plaque psoriasis. Approximately 574 subjects with mild to moderate plaque psoriasis will be randomized 1:1 to receive either apremilast 30 mg BID or placebo for the first 16 weeks.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Total Skin & Beauty Dermatology Center | Birmingham, Alabama, United States | — |
| Johnson Dermatology Clinic | Fort Smith, Arkansas, United States | — |
| Northwest Arkansas Clinical Trials Center, PLLC / Hull Dermatology | Rogers, Arkansas, United States | — |
| Dermatology Research Associates | Los Angeles, California, United States | — |
| TCR Medical Corporation | San Diego, California, United States | — |
| University of California San Francisco Psoriasis and Skin Treatment Center | San Francisco, California, United States | — |
| Clinical Science Institute | Santa Monica, California, United States | — |
| University of Colorado Hospital - Dermatology Clinic | Aurora, Colorado, United States | — |
| Total Vein and Skin, LLC | Boynton Beach, Florida, United States | — |
| Florida Academic Centers Research and Education | Coral Gables, Florida, United States | — |
| International Dermatology Research | Miami, Florida, United States | — |
| Center for Clinical and Cosmetic Research | Miami, Florida, United States | — |
+ 52 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03721172